Work

Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer

Year: 2015

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-15-b118

Authors: Gregory Cote, Kyriakos Papadopoulos, Amita Patnaik, Drew Rascoe, Lon Smith, Andrea Bullock, Keith Flaherty, Geoffrey Shapiro, Jordan Berlin, Manish Monga, Thomas Habermann, Thomas Witzig, Chester Lin, Lin-Feng Tsai, Agnes Elekes, Naoto Ohi, Kunihiko Tatsumi, Anthony Tolcher

Institutions: Massachusetts General Hospital, South Texas Accelerated Research Therapeutics, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Vanderbilt-Ingram Cancer Center, Mayo Clinic, Otsuka (United States), Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)

Language: English

Topic: Cytokine Signaling Pathways and Interactions

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2404348976

Cites:

Cited by:

Related to: 10